Genestra Echinacea Mix- 2 fl oz (60 ml)
• Three species of Echinacea, angustifolia, purpurea and pallida in liquid • Traditionally used in Herbal Medicine to help relieve the symptoms of upper respiratory tract infections and sore throats (1) • Ideal for vegans • Convenient liquid format increase patient compliance • Echinacea Mix is a unique preparation of the three species of Echinacea - angustifolia, purpurea and pallida, traditionally used in Herbal Medicine to help relieve sore throats and the symptoms of upper respiratory tract infections (2) .
References: 1 NHPD Monograph on Echinacea Angustifolia. June 2008. 2 NHPD Monograph on Echinacea Angustifolia. June 2008.
Additional product info: Both Echinacea purpurea and Echinacea angustifolia appear to activate non-specific cellular and humoral immunity and the complement system. Both of these species stimulate the immune system by increasing the production and activity of leukocytes, lymphocytes, and monocytes, as well as cytokines. E. purpurea and E. angustifolia have been shown to enhance the immune system in both animal models and clinical trials. In clinical studies, Echinacea reduced symptoms of common cold, influenza, and acute respiratory infections. Randomized controlled trials demonstrate significant reduction in cold symptoms, increased length of time between infections, and more rapid resolution of viral infections. A randomized, double-blind, placebo-controlled trial was conducted to address the following: (1) to compare the combination therapy to monotherapies of Echinacea and larch arabinogalactan; (2) to assess immunological out- comes following a treatment period of four weeks; and (3) to assess quality of life outcomes of the intervention. 48 female participants were selected to participate and randomly assigned to one of six groups : 1) E. purpurea whole herb extract (4% phenols; 1.5 g/day) (EP); (2) E. purpurea whole herb extract (4% phenols; 780 mg/day), ultra-refined E. purpurea whole herb, and E. angustifolia root (680 mg/day) (urEPA); (3) E. purpurea whole herb extract (4% phenols; 908 mg/day), E. purpurea whole herb (464 mg/day), and E. angustifolia root (36 mg/ day) (EPA); (4) E. purpurea whole herb extract (4% phenols; 908 mg/day), E. purpurea whole herb (464 mg/day), E. angustifolia root 36 mg/ day, and larch arabinogalactan (90%; 1.5 g/day) (EPALA); (5) larch arabinogalactan (90%; 1.5 g/ day) (LA); or (6) placebo (alfalfa and rice flour; 1.5 g/day). All subjects took daily doses of the supplement on an empty stomach for four weeks, two capsules in the morning and at bedtime. Volunteers in the E. purpurea/E. angustifolia and E. purpurea/E. angustifolia plus larch arabinogalactan groups had increased production of complement properdin after four weeks of intervention. The increased complement properdin may be an indication of one aspect of immune system stimulation in patients treated with either E. purpurea/E. angustifolia or E. purpurea/E. angustifolia plus larch arabinogalactan (3). In a randomized, double-blind, placebo-controlled trial, 282 subjects aged 18–65 years with a history of two or more colds in the previous year, but otherwise in good health, were recruited. The subjects were randomized to receive either echinacea purpura or placebo. They were instructed to start the echinacea or placebo at the onset of the first symptom related to a cold, consuming 10 doses the first day and four doses per day on subsequent days for 7 days. Each dose consisted of 4-mL formulation. The extracts were combined in 40% ethanol to provide an echinacea formulation containing alkamides/cichoric acid/polysaccharides at concentrations of 0.25/2.5/25.5 mg/mL, respectively. The total daily symptom scores were found to be 23.1% lower in the echinacea group than in placebo in those who followed all elements of the study protocol. Early intervention with a standardized formulation of echinacea resulted in reduced symptom severity in subjects with naturally acquired upper respiratory tract infection (4). In another study by the same authors, Echinilin?(same formulation as previous study) or placebo were administered to volunteers at the onset of their cold for a period of 7 days, with eight doses (5 mL/dose) on day 1 and three doses on subsequent days. Fasting blood samples were obtained before and during their colds. The decrease in total daily symptomatic score was more evident in the echinacea group than in the placebo group. These effects of echinacea were associated with a significant and sustained increase in the number of circulating total white blood cells, monocytes, neutrophils and NK cells. In the later part of the cold, the echinacea treatment suppressed the cold-related increase in superoxide production by the neutrophils. These results suggest that EchinilinTM, by enhancing the non-specific immune response and eliciting free radical scavenging properties, may have led to a faster resolution of the cold symptoms (5).
References: 3 Kim LS, Waters RF, Burkholder PM. Immunological activity of larch arabinogalactan and Echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. Altern Med Rev. 2002 Apr;7(2):138-49. 4 Goel V, Lovlin R, Barton R, Lyon MR, Bauer R, Lee TD, Basu TK. Efficacy of a standardized echinacea preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2004 Feb;29(1):75-83. 5 Goel V, Lovlin R, Chang C, Slama JV, Barton R, Gahler R, Bauer R, Goonewardene L, Basu TK. A proprietary extract from the echinacea plant (Echinacea purpurea) enhances systemic immune response during a common cold. Phytother Res. 2005 Aug;19(8):689-94.